Alcon, analysts point to a clear Buy consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 21:37.

Alcon (CH0432492467) comes into Tuesday with a clear analyst backdrop on Switzerland-focused coverage. Investing.com lists 17 analysts, 22 Buy recommendations, and an average 12-month target of 77.49 Swiss francs according to the consensus page.

What the analysts say

The same page shows one Sell rating and three Hold calls, which leaves the Buy camp dominant. It also shows a high target of 89.60 Swiss francs and a low target of 51.92 Swiss francs.

That puts the current discussion around a wide range of views, not a single price point. The consensus page also translates that into a potential upside of 46.27 percent.

Tuesday's consensus picture

Tuesday's focus is the analyst split, and the numbers are explicit. With 22 Buy recommendations and 17 analysts in the sample, the tone on Alcon stays constructive in the latest published consensus set in the StockScan forecast table.

For an international anchor, the stock is covered in Switzerland-linked market data, while the broader comparator set used by investors often includes other large healthcare names in Europe and the US. That makes the current consensus framing easy to place alongside peer discussions on valuation and earnings quality.

What Alcon sells

Alcon's core business centers on eye care, with contact lenses and surgical products as its main commercial pillars. The company serves both consumer and medical channels through a broad ophthalmology portfolio.

Where Alcon trades today

The Alcon shares (CH0432492467) trade on the SIX Swiss Exchange. The latest live-verified price was not included in the available source set, so the Swiss listing remains the key reference point here.

Disclaimer: This article is for information only and does not constitute investment advice.